cyrilzakka/clinical-trials huggingface dataset:
Risk of Falling in Chronic Kidney Disease 5

The purpose of this study is to explore the relative importance of the frailty and cardiovascular function as potential exercise-modifiable risk factors for falling in patients receiving haemodialysis.

Falls and fall-related injuries in elderly people are common worldwide, and ageing populations will further raise the burden and costs. Within the UK, falls have become a major government target, as they have been responsible for increased injuries and hospital admissions in elderly people.

The fall rate amongst patients on haemodialysis (HD) is much greater than in the general population. There are many well established risk factors for falling, many of which are commonly present in patients on HD, including severe loss of muscle mass, high levels of inactivity, co-existing medical conditions and a high number of medications.

Nonetheless, the main cause of health complications and death in Chronic Kidney Disease (CKD) is due to cardiovascular disease. Cardiovascular disease may result in suboptimal regulation of blood pressure and heart rate during exercise, dialysis therapy, body transfers, and general activities of daily living. Associated symptoms such as dizziness, generalised fatigue, and muscular weakness, are commonly reported and may further predispose patients on HD to balance deficits and falls.

Despite the evidence of high falls rates in patients on HD and the growing number of elderly patients, falls and their associated risk factors have received little research attention.

The aim of this study therefore is explore the relative importance of selected exercise-modifiable risk factors for falling amongst patients on HD.

Eligibility Criteria:
Inclusion Criteria:

* 18 years old
* Able to write/speak fluent English
* Stable dialysis

Exclusion Criteria:

* Unstable dialysis and medication treatment
* Lower limb amputees without prothesis
* Unstable cardiac condition
* Suspected or known aneurysm
* Clinically severe left ventricular outflow obstruction
* Critical mitral stenosis
* Critical proximal coronary artery stenosis
* Critical cerebrovascular stenosis
* Pregnancy
* Severe cognitive impairment
Total Knee Replacement With Duracon® and Vanguard™ Prostheses

The purpose of this study is to compare range of motion, Knee Society Scores, and duration of surgery for different total knee prostheses.


Eligibility Criteria:
Inclusion Criteria:

* Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.
* Patients requiring correction of varus, valgus, or posttraumatic deformity.
* Patients requiring correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Exclusion Criteria:

* Patients with infection, sepsis, or osteomyelitis.
A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia

The purpose of this study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) in patients with insomnia by a randomized, double-blind, group-comparison study using zolpidem (Myslee) as a comparative drug


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of nonorganic insomnia.
* Must be able to swallow tablets

Exclusion Criteria:

* Allergic reactions to zolpidem (Myslee)
* Serious cardiac disorders; Serious hepatic impairment; Serious renal diseases, etc.
Comparison of Acute Effects of Myofascial Release and Kinesio Taping® in Dysmenorrhea

Dysmenorrhea is a physiological condition and one of the most common issues experienced during menstruation. This study aims to compare the acute effects of Myofascial Release Technique (MRT) and Kinesio Taping® (KT) on pain severity, fatigue, and menstrual symptom severity in individuals with primary dysmenorrhea (PD).

A total of 45 individuals diagnosed with PD will be randomly assigned to one of three groups: MRT, KT, or control. Pain severity and fatigue will be measured using the Visual Analog Scale (VAS), while menstrual symptom severity will be assessed with the Menstrual Symptom Scale, both prior to and following the interventions. The MRT group will be received MRT for three consecutive days starting from the onset of menstruation, whereas the KT group will be applied KT application for a duration of 72 hours. The control group did not receive any form of intervention.

Eligibility Criteria:
Inclusion Criteria:

* Daignosed with primary dysmenorrhea
* Regular menstruation in the past six months
* Experience menstrual pain ranging between 40-100 mm on the Visual Analog Scale

Exclusion Criteria:

* Diagnosis of secondary dysmenorrhea
* A menstrual cycle length of less than 21 days or more than 35 days
* A history of childbirth or pregnancy
* Use of pharmacological treatments for menstrual pain
* A history of pelvic pathology or pelvic surgery
* The presence of neurological or systemic diseases
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease

While people of color are an increasing segment of the inflammatory bowel disease (IBD) population, they are currently underrepresented in research, including studies of psychological distress. Appreciation for psychological distress (anxiety, depression, perceived stress) as a driver of IBD activity has led to increased efforts to integrate psychological interventions into IBD medical care. Cognitive behavioral therapy (CBT) is the most studied psychotherapeutic approach in IBD and the one that suggests improvements in mental health and quality of life in those with elevated psychological distress. There are unanswered questions in the use of CBT in IBD: how to leverage digital technology to deliver CBT through internet-based cognitive behavioral therapy (iCBT); how do we consider the social context of individuals from racial and ethnic minority groups who may experience distinct social and structural barriers to acceptance and use of psychological interventions? Thus, this study will qualitatively analyze how factors, such as digital access, mental health stigma, and lived experience with IBD and as racial or ethnic minority influence attitudes toward mental health and iCBT in a cohort of Black and Latino IBD patients with elevated psychological distress. Results will lead to adaptation of a CBT program into an iCBT app to be tested for acceptance/use and to explore effects on psychological and disease-related factors.


Eligibility Criteria:
Inclusion Criteria:

* self-identify as Black or Hispanic/Latino
* diagnosis of Crohn's disease or ulcerative colitis
* ability to provide informed consent in English
* basic computer skills (i.e. ability to self-complete online questionnaire)
* elevated psychological distress

Exclusion Criteria:

* severe psychological distress
* active suicidality, past suicide attempt, or psychiatric hospitalization
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China

This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course (concomitantly use no later than the 3rd TACE procedure) has been made under real-life practice conditions.this study will also conclude the safety and effectiveness of combination in uHCC patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients with histologically/ cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made. Radiographic diagnosis needs typical findings of HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or MRI;
* Patients receive the first dose of sorafenib no later than 1 week (\<=7days) after the 3rd TACE procedure
* Patients did not receive other prior systemic treatment by using target therapy
* Patients must sign the informed consent form;
* Patients must have a life expectancy of at least 3 months;
* The physician must be willing to complete and submit all CRFs;
* The physician must be willing to submit to a site audit with verification of source documents and validation of data reported;

Exclusion Criteria:

* The first dose of sorafenib 7 days after the 3nd TACE procedure
* Exclusion criteria must follow the approved local product information
Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

This randomized clinical trial studies expressive writing in improving the wellbeing or comforting capacity of caregivers of patients with cancer. Expressive writing is a type of intervention that asks people to write about important topics (in this case participants' experience with their spouses'/partners' cancer) and their emotions/feelings surrounding them. Expressive writing, including benefit finding and traumatic disclosure, may be a type of at-home-therapy that caregivers can utilize in an attempt to increase their own wellbeing, offer better comfort to cancer patients, and by association, help cancer patients cope with and manage the cancer experience.

PRIMARY OBJECTIVES:

I. To test whether one, or both, types of expressive writing impact spouses of cancer survivors' reported emotional wellbeing and reported ability to provide comfort as compared to a control group.

OUTLINE: Patients are randomized to 1 of 2 arms or assigned to a control arm.

ARM I (EXPRESSIVE DISCLOSURE): Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.

ARM II (BENEFIT FINDING): Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.

ARM III (CONTROL): Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.

After completion of study, participants are followed up at day 17.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be a spouse or domestic partner of a cancer survivor and will be recruited via the Hematopoietic Stem Cell Transplant Database at Fred Hutchinson Cancer Research Center (FHCRC)
* Participants must have been in their spousal relationship for at least the past 1 year

Exclusion Criteria:

* If participants are unable to access a computer they will be excluded
FitMi AD Home Therapy for Individuals with MCI or Mild Dementia Due to Alzheimer's Disease

This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. FitMi AD uses embedded sensors that can track and record the patient's direction and degree of movement while performing exercises described on a computer.


Eligibility Criteria:
Inclusion Criteria:

* have MCI or mild dementia due to AD (i.e. Clinical Dementia Rating (CDR) score 1 for mild dementia or 0.5 for MCI)
* ability to clearly see the screen and hear the audio instructions from the tablet
* have a family member or friend who can answer questions about the participant's daily living skills
* willing to participate in a research study.

Exclusion Criteria:

* age \< 50 years old
* use of a wheelchair as a primary mobility device (use of a cane or walker is permitted)
* presence of other neurologic conditions such as movement disorders or history of stroke
* other severe concurrent medical conditions that may prevent the participants from completing the 3-month study
A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine

This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.


Eligibility Criteria:
Inclusion Criteria:

* Ethnically Korean with a diagnosis of chronic migraine

Exclusion Criteria:

* Anticipated need for botulinum toxin treatment for any reason other than chronic migraine during the study
* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)

Patients with hepatocellular carcinoma and esophageal varices bleeding were randomized to undergo endoscopic ligation alone (group A) and additive propranolol treatment (group B) after stabilization of their first acute bleeding.

Esophageal variceal bleeding is characteristic of high rebleeding rate and mortality. Thanks to the recent advance of treatment for variceal bleeding such as non-selective beta blocker (NSBB) added to endoscopic ligation further reduce rebleeding in cirrhotic patients, the rebleeding rate and mortality has a marked reduction. However, hepatocellular carcinoma (HCC) is a distinct group characteristic of very poor prognosis in patients with portal hypertension when compared to those of liver cirrhosis only. Therefore, the investigators design a study to randomize patients with HCC and acute variceal bleeding to endoscopic treatment alone and combination with endoscopic treatment and NSBB. This is the two years study.

Eligibility Criteria:
Inclusion Criteria:

1. clinical diagnosis of HCC
2. endoscopically proven acute variceal bleeding
3. younger than 18 years old or older than 80 years old

Exclusion Criteria:

-Had a terminal illness of any major organ system,such as heart failure, kidney failure,COPD
Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy

To evaluate the benefit for statin use in prevention of of CI-AKI after computed tomography urogram (CTU).


Eligibility Criteria:
Inclusion Criteria:

* Planned computed tomography urogram (CTU)
* Statin naive, or not on statin treatment for at least 14 day

Exclusion Criteria:

* History of liver disease or elevated serum transaminases
* History of rhabdomyolysis or elevated creatinine kinase
* History of iodinated CM use within 14 days before randomization
* History of N-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure.
* History of hypersensitivity reaction to contrast media
* Pregnancy or lactation
* Acute renal failure
* End-stage renal disease requiring dialysis
* Cardiogenic shock or pulmonary edema
* Multiple myeloma
Acute Effects of Dynamic Stretching, Plyometrics, and Loading on Achilles Tendon Properties and Performance Outcomes

The study will be looking at acute changes in Achilles tendon properties and changes in a vertical single leg hop following an exercise intervention. The three exercise interventions will be randomized and take place on separate days 1 week apart. The three exercise interventions are AAROM, slow load, and plyometrics.

The purpose of the study is to determine if there are acute changes in Achilles tendon properties and changes in performance based on what tendon exercise intervention is being used. About 70 people will take part in this research.

Eligibility Criteria:
Inclusion Criteria:

* College student

Exclusion Criteria:

* Unable to complete interventions
WhatsApp in India During the COVID-19 Pandemic

Digital misinformation has been flagged as a major risk of the 21st century, with an estimated cost of $78 billion to the global economy each year. Given this scope, we propose to characterize how misinformation is spread via messenger platforms (e.g. WhatsApp).

Specifically, we seek to:

1. Identify metrics of potential misinformation (Aim 1). This is based on the hypothesis that although message contents are highly private, proxy markers can be used to identify potential misinformation.
2. Understand the base-rate by which misinformation is shared via messaging applications (Aim 2). This is founded on the hypothesis that misinformation is endemic on messaging platforms, and thus needs to be documented.
3. Identify "super spreaders" responsible for sending and receiving a large volume of misinformation (Aim 3). Here, we hypothesise that a small group of super spreaders are responsible for the bulk of misinformation-sharing on messaging applications.

The thrust of this work aligns with both government priorities and the grant's thematic areas, providing actionable findings that are timely amidst a worldwide surge of misinformation.


Eligibility Criteria:
Inclusion Criteria:

* Lived in India for more than 2 years,
* Currently Living in India
* Owns a WhatsApp account

Exclusion Criteria:

* Not currently living in India
* Below the ages of 21
* Has not lived in India for more than 2 years
* does not own a WhatsApp account
* Does not speak English or Hindi
A Multi-center Human Study to Evaluate the Efficacy and Safety of ®GI Flora in Subjects With Irritable Bowel Syndrome

A Multi-center, Randomized, Double-blinded, Placebo-controlled Human Study to Evaluate the Efficacy and Safety of probiotic mixture(®GI Flora) in Subjects with Irritable Bowel Syndrome.

Regimen: 6 probiotics mixture \>10\^9/D for 8 weeks

Primary variable: visual analogue scale(VAS) assessment for abdominal pain

Secondary variable:

1. change of VAS score for abdominal pain/discomfort after 4/8-week treatment
2. daily symptom score for bloating, defecation discomfort(strain/urgency/incomplete evacuation), flatulence , feces shape, frequency of bowel movements


Eligibility Criteria:
Inclusion Criteria:

* Irritable bowel syndrome patients according to Rome III criteria
* Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: a) improvement with defecation; b) onset associated with a change in the frequency of stool; c) onset associated with a change in form (appearance) of stool.

Exclusion Criteria:

* Intolerable or hypersensitive to GI Flora.
* Patients with active colon diverticulitis.
* History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation.
* History of inflammatory bowel disease, malignancy requiring surgery or chemotherapy or radiation within 5 years.
* Patient has any condition that, in the opinion of the Investigator, would compromise the well-being of the patient or the requirements of the study.
CBT-I as Early Intervention of Mood Disorders

This study aims to investigate the effectiveness of transdiagnostic nurse-administered 4-session group cognitive behavioral therapy for insomnia (CBT-I) plus standard care, compared to standard care alone, for improving sleep and daytime function, enhancing recovery, preventing relapses, and reducing medication burden in patients with the first episode of mood disorders.


Eligibility Criteria:
Inclusion Criteria:

* Hong Kong residents
* Aged ≥ 18 years
* Able to to communicate in Cantonese and write in Chinese
* First episode of depressive or bipolar disorders according to the DSM-5 diagnostic criteria
* Having received psychiatric treatment for less than 12 months
* Meeting the DSM-5 diagnostic criteria for insomnia disorder for at least 1 month, instead of at least 3 months, as in criterion D.

Exclusion Criteria:

* Significant cognitive impairments and psychotic symptoms, based on a Mini-mental State Examination score of 23 or below and the Positive and Negative Syndrome Scale items on delusions, conceptual disorganization, and hallucinatory behavior at moderate severity or above
* A diagnosis of schizophrenia, delusional disorder, neurocognitive disorders, or learning disability
* Having a highly unstable medical or psychiatric condition (including strong suicidal risk) that requires hospitalization
* Having an untreated sleep disorder, including narcolepsy, obstructive sleep apnea, and periodic leg movement disorder
* Past or current treatment with CBT-I
* Having a fear of speaking in a group setting or refusal to give informed consent
* Refuse to give informed consent
ADHEPTA Study: Adherence Questionnaire in Hepatitis C

Main objective: To study and validate a questionnaire measuring treatment adherence in patients with Hepatitis C virus (HCV) infection.

Design of the study: Multicentric, prospective, epidemiological study in the field of usual clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Ambulatory patient infected by HCV according to diagnosis criteria used en usual clinical practice.
* Patient no treated previously and beginning a treatment for HCV.
* Patient that signed the informed consent to participate in the study.
* Group A: patient with HCV monoinfection.
* Group B: patient with HCV and HCV co-infection (according to diagnosis criteria used en usual clinical practice).

Exclusion Criteria:

* Patient that received previous treatment for HCV.
* Patient that is going to participate in a clinical trial Turing the HCV treatment period.
* Patient with cognitive impairment or patient unable to understand and answer the auto-administered questionnaire.
* Patient unable to read or write Spanish.
Electroacupuncture Regulation of Immune Cells in Herpes Zoster

Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life. The immune system is critical in HZ pathogenesis. Studies show acupuncture relieves pain, modulates immunity, and may lower postherpetic neuralgia (PHN) risk. However, evidence is limited on whether electroacupuncture (EA) alleviates HZ by modulating immune cells. Using mass cytometry (CyTOF), this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity. This study will recruit HZ patients and healthy controls (HC), dividing patients into medication-only and medication+EA groups to assess EA's potential immunomodulatory effects in HZ treatment.

The study will enroll 8 HZ patients who meet the inclusion criteria and 3 age- and gender-matched healthy controls (HC). HZ patients will be randomly assigned in a 1:1 ratio to a medication-only group or a medication plus electroacupuncture group. All participants will receive Valacyclovir Hydrochloride tablets and Mecobalamin tablets. HZ-related immune cells in peripheral blood will be analyzed using CyTOF before treatment (day 0), during treatment (day 4), and after treatment (day 7). Pain intensity and characteristics will be assessed using the Visual Analogue Scale (VAS) and the Douleur Neuropathique 4 (DN4) questionnaire. Lesion healing (time to vesicle cessation, crusting, and scab detachment) and adverse events will also be recorded to evaluate lesion regression in HZ patients.

Eligibility Criteria:
Inclusion Criteria for HZ:

* Meets HZ diagnostic criteria;
* Female, aged between 50 and 70 years;
* Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;
* Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;
* Willing to participate in the trial and has signed the informed consent form.

Inclusion Criteria for HC:

* No history of HZ or major cardiovascular, respiratory, digestive, urinary, hematologic, endocrine, or neurological diseases;
* Age-matched female HC volunteers for the HZ group;
* Clear consciousness and ability to communicate normally;
* Fully understands the study protocol, demonstrates good compliance, and is willing to cooperate with the study;
* Has signed a written informed consent form.

Exclusion Criteria:

* Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;
* Women who are planning to conceive, pregnant, or breastfeeding;
* Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;
* Patients with bleeding tendencies;
* Use of corticosteroids or immunosuppressants within the past month.